Compositions and a method are provided for the treatment of prostate and otherendocrine tumors in mammals, including humans, by administration of anantisense oligodeoxynucleotide (ODN) which is complementary to a portion ofthe gene encoding IGFBP-2. Using the human prostate cancer LNCaP tumor modelin vitro andin vivo, the administration of such an ODN was shown to reduceproliferation of tumor cells, and also to delay the progression to androgenindependence. Thus, treatment of prostate and other hormone-regulated cancerin mammals, including humans, and delay of the progression of prostate tumorsto androgen independence is accomplished by administering to the mammal atherapeutically effectie amount of an antisense oligodeoxynucleotide which iscomplementary to a portion of the nucleic acid sequence encoding IGFBP-2 andwhich reduces the amount of IGFBP-2 in the treated cells.
展开▼
